<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Parliamentary Inquiry on blood tissue and organ screening for vCJD</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">National Institute of Biological Standards and Control </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">(BTO00005)</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A test that could identify individuals infected with the agent of </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> would be of enormous value. It could help in evaluating treatments and could clarify whether individuals who have been informed they are at risk based on theoretical evaluation are indeed infected. It could establish the prevalence of infection in the UK and therefore place risk evaluations which have to use the most pessimistic assumptions on a realistic basis.  Such evaluations, and potentially any developed tests, have serious consequences, including the distress of individuals informed that they may be infected and the very expensive mitigations that have been put in place to minimise onward transmission. For instance plasma from the UK is discarded rather than being used to prepare medicinal products such as clotting factors or </span><span style="font-family:'Times New Roman'; font-size:11pt">immunoglobulins</span><span style="font-family:'Times New Roman'; font-size:11pt"> and serious consideration has been given to introducing </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> removal filters into the blood transfusion process for every donation.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A test that wrongly identifies uninfected individuals as infected would be totally unacceptable, depending on the frequencies of false results obtained. For example a test could be introduced in the blood transfusion service with a hypothetical situation in which 2 million donations were tested. If the test recorded 99% of uninfected people correctly but gave a false positive rate of 1% 20000 people would be wrongly identified as infected in the first year alone; they would have to be informed and given appropriate counselling and could not be distinguished from those truly infected unless an additional more reliable  confirmatory test or tests were available. Considerations of this kind by the Department of Health and others such as the Blood Transfusion Services lead to the conclusion that independent advice on test performance is essential.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">For common blood borne infections (such as for Hepatitis B) suitable samples can be sourced specifically for test development and very large numbers obtained, including those taken at different times during the incubation period. Such samples are not available for </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">. There have been thankfully less than two hundred cases of </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">. There are few samples from </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> patients available and they have been taken in small volumes from the patients for clinical purposes. Discussions between the Department of Health and the Units who had stored materials concluded that access, by those test developers without access to their own sources, to the relatively small number of samples should be controlled and only those assays that were most likely to be successful given access to the very rare samples from known </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> patients. NIBSC was involved in these discussions because of its experience in developing, storing and dispatching reference materials and its collaboration with the Blood Transfusion Services in providing control materials for testing for blood borne pathogens.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt"> The CJD Resource Centre at NIBSC has access to samples from some of the patients and has been able to source a portion of those samples. They do not store samples from all patients or the entire sample that has been taken, the remaining material being kept at the clinical centres.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">It was assumed that a viable test will involve analysing blood or a blood component as the most accessible and consistent sample type.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">It was further assumed that tests will be directed at detection of the abnormal form of the </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> protein which is believed to be the infectious agent. The significance of a positive finding is, however, open to interpretation.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Work on </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> at NIBSC began in 2000 with the receipt of materials from the National CJD Research and Surveillance Unit in Edinburgh intended for development of WHO reference materials. The materials (two samples of brain from cases of sporadic CJD, one from a case </span><span style="font-family:'Times New Roman'; font-size:11pt">of variant CJD and one non CJD control) were established as WHO reference reagents in 2003 by the Expert Committee on Biological Standardisation (Attachment 1).</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Specific funding for the CJD Resource Centre at NIBSC from DH began in 2001.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Funding was renewed in 2012.</span></li></ol><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">An Oversight Committee was established to monitor and direct the work of the NIBSC based CJD Resource Centre when it became clear that a number of laboratories were at a reasonable stage of assay development. The first meeting was held in April 2007. The membership of the committee was intended to include representatives of all interested parties including scientific laboratories, the Blood Transfusion Services, the units with samples, the Animal Health and Veterinary Laboratories Agency at Weybridge and patient groups. The Department of Health attended as observers (current membership is at Attachment 2).</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Terms of Reference were agreed in October 2007 (Attachment 3) and revised in 2013 (attachment 4). They were concerned with access to the very rare samples of blood from patients with </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">, and how a test would qualify for such access. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">An algorithm for access to the rare samples was established in 2007 (Attachment 5). It involves evaluation of the test for suitability by using more readily available samples including those from animal models, and is therefore similar in principle to the kind of technical evaluation envisaged for assessment of suitability for use in testing of patients. The Oversight Committee would not make the decision on suitability for use in patients, however, but pass this to other groups, such as the UK blood services </span><span style="font-family:'Times New Roman'; font-size:11pt">Prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> Working Group (PWG) with whatever data had been accumulated.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The algorithm includes justification for the approach taken, caveats concerning the assumptions made and clear statements that failure to meet the criteria at any stage is not fatal to the assay but should lead to scientific discussion (Attachment 5). The decision to cease the evaluation lies with the developer alone. The acceptance that the results justify progress to the next stage is the responsibility of the Committee. It is absolutely key to the process that the materials are assayed blind by the developer to allow an unbiased judgement.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Collaboration between developers and the Resource Centre is close, including visits to the developers’ laboratories and supervised assessments by the developers at the laboratories of NIBSC. The Resource Centre responds to the comments and needs of the developer with respect to the nature of the samples distributed, for instance in the types of additive present. This is to ensure that the assessments are seen as fair, comprehensive and objective by all parties and the assay is given every chance of success.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The results are published (Attachment  6) when completed. A summary of materials sent out is given in Attachment 7.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In practice no developer has followed precisely all the terms of the algorithm as written. The terms are adapted according to the evidence and specific scientific arguments relevant to each test.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="17" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The range of samples available includes materials from clinically affected and normal human and animal brain, spleen, plasma and other blood components. Diseases include </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> and classical CJD of humans, </span><span style="font-family:'Times New Roman'; font-size:11pt">scrapie</span><span style="font-family:'Times New Roman'; font-size:11pt"> of sheep and </span><span style="font-family:'Times New Roman'; font-size:11pt">bse</span><span style="font-family:'Times New Roman'; font-size:11pt"> of cows. There are also samples that are the product of experimental infection donated to the collection by laboratories other than NIBSC. Detailed aspects of the samples such as how they have been preserved and the type of anticoagulants used have been raised by the developers and suitable adjustments made, and where necessary additional samples have been prepared to meet an individual developers </span><span style="font-family:'Times New Roman'; font-size:11pt">specific requirements. The use of the samples in practice is briefly summarised in Attachment 7.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="18" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Two developers have followed the evaluation process to the end, showing acceptable performance in terms of acceptable sensitivity, a high degree of reproducibility and a high degree of specificity. Neither gave positive results when access to the very rare samples from clinical </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> patients was eventually granted. Other assays have failed in terms of poor assay reproducibility or unexplained variations in results and not been pursued further by the developers.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="19" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Oversight Committee algorithm helped in formulating the Common Technical Specification associated with the inclusion of tests for </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> in plasma into Annex IIA of the EU In Vitro Devices Directive. The inclusion in Annex IIA provides clear requirements for the marketing of such tests and prevents tests of poor reproducibility specificity and sensitivity being introduced. As the potential consequences for individuals of testing with poor tests are unthinkable this classification was thought vital.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">December 2013</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Attachments</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 27.45pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt"> Minor, P., Newham, J., Jones, N., Bergeron, C., </span><span style="font-family:'Times New Roman'; font-size:11pt">Gregori</span><span style="font-family:'Times New Roman'; font-size:11pt">, L., Asher, D., van </span><span style="font-family:'Times New Roman'; font-size:11pt">Engelenburg</span><span style="font-family:'Times New Roman'; font-size:11pt">, F. et al  Standards for the assay of Creutzfeldt-Jakob disease specimens (2004) Journal of General Virology, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">85 6</span><span style="font-family:'Times New Roman'; font-size:11pt">, Pages </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">1777-1784.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 27.45pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Membership of the CJD Oversight Committee December 2013.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Philip Minor (NIBSC,MHRA)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Noel Gill (PHE) </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Jillian Cooper (NIBSC, MHRA)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Jean Manson (</span><span style="font-family:'Times New Roman'; font-size:11pt">Roslin</span><span style="font-family:'Times New Roman'; font-size:11pt"> Institute)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Richard Knight (CJDRSU)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Simon Mead (MRC </span><span style="font-family:'Times New Roman'; font-size:11pt">Prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> Unit)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Neil Almond (NIBSC, MHRA) </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr David </span><span style="font-family:'Times New Roman'; font-size:11pt">Anstee</span><span style="font-family:'Times New Roman'; font-size:11pt"> (NHSBT)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Robert Will (CJDRSU)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Maurice </span><span style="font-family:'Times New Roman'; font-size:11pt">Bardsley</span><span style="font-family:'Times New Roman'; font-size:11pt"> (VLA) </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Jim Hope (VLA)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Christine Lee (Royal Free Hospital, retired)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Gill Turner (CJD Support Network)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Professor Marc Turner (NHSBT)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt"> Professor Janet </span><span style="font-family:'Times New Roman'; font-size:11pt">Darbyshire</span><span style="font-family:'Times New Roman'; font-size:11pt"> (MRC, retired)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr </span><span style="font-family:'Times New Roman'; font-size:11pt">Micha</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Nuebling</span><span style="font-family:'Times New Roman'; font-size:11pt"> (Paul Ehrlich Institute, Germany)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Joliette </span><span style="font-family:'Times New Roman'; font-size:11pt">Coste</span><span style="font-family:'Times New Roman'; font-size:11pt"> (French Blood Transfusion Service)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Stephen Lee (MHRA)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Nick Andrews (PHE)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Mark </span><span style="font-family:'Times New Roman'; font-size:11pt">Noterman</span><span style="font-family:'Times New Roman'; font-size:11pt"> (DH)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Gary </span><span style="font-family:'Times New Roman'; font-size:11pt">Mallinson</span><span style="font-family:'Times New Roman'; font-size:11pt"> (NHSBT)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><br style="page-break-before:always; clear:both" /></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 27.45pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Resource Centre Oversight Committee: Terms of Reference 2007</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 48.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To oversee the establishment of an archive of blood samples and blood components from patients with all types of CJD and persons at risk, with particular focus on </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> (subject to revision as needed.)</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 49.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To oversee the establishment of an archive of samples from animal models for all types and stages of human CJD including preclinical samples from TSE infected animals.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 48.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To devise a critical path of the steps required to allow ante mortem tests for human TSEs to be judged suitable for testing with rare samples.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 49.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To approve protocols for the studies to be performed when access is granted and review the data generated.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 48.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To oversee the distribution of rare samples from the facility.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 47.41pt; padding-left:6.59pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To ensure that all activities are performed in accordance with the Human Tissue Act and appropriate ethical standards.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 49.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To ensure coordination and liaison between the facility and oversight committee and other groups with overlapping interest including the </span><span style="font-family:'Times New Roman'; font-size:11pt">Prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> Assay Working Group of the Blood Transfusion Service.</span></li></ol><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 49.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To cooperate with European Bodies responsible for defining requirements for the diagnostic evaluation of </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> assays (for CE marking of IVDs).</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 27.45pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Terms of Reference (2013)</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 48.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Maintain an archive of blood and tissue samples from individuals with human </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> disease, persons with an increased risk of </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> disease and relevant healthy and disease controls.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 49.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Maintain an archive of animal samples that may represent animal models for all types of and stages of human </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> disease.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 48.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Develop protocols whereby wet ante mortem biomarker tests for human </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> disease may be evaluated, and to propose processes for the evaluation of such tests.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 49.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Perform evaluations of ante mortem tests referred to the Centre by the Oversight Committee.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 48.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Manage the distribution of samples from the archive</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 47.41pt; padding-left:6.59pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Ensure that all activities undertaken are compliant with ethical and legal requirements.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 49.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Ensure coordination and liaison between the Research and Resource Centre and the Oversight Committee with other advisory committees with overlapping interests.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 49.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Carry out relevant research to support the work of the Research and Resource Centre.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="color:#222222; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 27.45pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="color:#000000; font-family:'Times New Roman'; font-size:11pt">Algorithm for access to the rare patient samples</span><span style="color:#000000; font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> : CJD Resource Centre website: </span><span style="color:#222222; font-family:'Times New Roman'; font-size:11pt; font-style:italic">www.nibsc.org/Spotlight/</span><span style="color:#222222; font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">CJD</span><span style="color:#222222; font-family:'Times New Roman'; font-size:11pt; font-style:italic">_</span><span style="color:#222222; font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Resource</span><span style="color:#222222; font-family:'Times New Roman'; font-size:11pt; font-style:italic">_</span><span style="color:#222222; font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Centre</span><span style="color:#222222; font-family:'Times New Roman'; font-size:11pt; font-style:italic">.aspx</span><span style="color:#222222; font-family:'Times New Roman'; font-size:11pt">&#x200e;</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="color:#231f20; font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 27.45pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="color:#000000; font-family:'Times New Roman'; font-size:11pt">Publications related to assessments:  </span></li></ol><p style="margin:0pt 0pt 0pt 32.2pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Cooper, J.K., Andrews, N., </span><span style="font-family:'Times New Roman'; font-size:11pt">Ladhani</span><span style="font-family:'Times New Roman'; font-size:11pt">, K., </span><span style="font-family:'Times New Roman'; font-size:11pt">Bujaki</span><span style="font-family:'Times New Roman'; font-size:11pt">, E., &amp; Minor, P.D.. Evaluation of a test for its suitability in the diagnosis of variant Creutzfeldt-Jakob disease. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Vox</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Sanguinis</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt">2013, 105, (3) 196-204;   </span></p><p style="margin:0pt 0pt 0pt 32.2pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Cooper, J.K., K. Ladhani, and P. Minor, Comparison of candidate vCJD in vitro diagnostic assays using identical sample sets</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Vox Sanguinis</span><span style="font-family:'Times New Roman'; font-size:11pt">, 2012. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">102</span><span style="font-family:'Times New Roman'; font-size:11pt">(2): p. 100-9;  </span></p><p style="margin:0pt 0pt 0pt 32.2pt; text-align:justify"><span style="color:#231f20; font-family:'Times New Roman'; font-size:11pt">J. K. Cooper, K. </span><span style="color:#231f20; font-family:'Times New Roman'; font-size:11pt">Ladhani</span><span style="color:#231f20; font-family:'Times New Roman'; font-size:11pt"> &amp; P. D. Minor Reference materials for the evaluation of pre-mortem variant Creutzfeldt–Jakob disease diagnostic assays </span><span style="color:#231f20; font-family:'Times New Roman'; font-size:11pt; font-style:italic">Vox</span><span style="color:#231f20; font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="color:#231f20; font-family:'Times New Roman'; font-size:11pt; font-style:italic">Sanguinis</span><span style="color:#231f20; font-family:'Times New Roman'; font-size:11pt"> (2007) </span><span style="color:#231f20; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">92</span><span style="color:#231f20; font-family:'Times New Roman'; font-size:11pt">, 302–310</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 27.45pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt"> Samples dispatched in assessments</span><a name="_GoBack"></a></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The aim of the CJD resource centre and its oversight committee is to ensure fair and appropriate access to extremely rare blood components from clinical cases of </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">.  Samples used in these studies were generated by NIBSC in collaboration with other TSE research groups who supplied animal samples (AHVLA and </span><span style="font-family:'Times New Roman'; font-size:11pt">Roslin</span><span style="font-family:'Times New Roman'; font-size:11pt">); the CJD Surveillance unit and the MRC </span><span style="font-family:'Times New Roman'; font-size:11pt">Prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> clinic who provided CJD samples and the UK National Blood and Transfusion Service who provided normal donor samples.  Both test sensitivity (how little infectious material can be detected) and specificity (number of samples incorrectly scored positive) studies were performed.  </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Completed evaluation studies:</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Company A</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Samples  provided:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Spiked panel sets (</span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> tissue homogenates in pooled human plasma</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2006</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">48 samples)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Sheep plasma samples (</span><span style="font-family:'Times New Roman'; font-size:11pt">Scrapie</span><span style="font-family:'Times New Roman'; font-size:11pt">, BSE infected and Control; total 250)</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2008</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">UK blood donor plasma (1000 individuals, unfrozen, prepared </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2008</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">daily at NIBSC)</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Primate plasma (BSE infected and controls; total 60)</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2009</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">UK donor plasma (Frozen set, 1000 individuals)</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2009</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Variant and Sporadic CJD plasma (3 variant, 2 sporadic)</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">along</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2009</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">With normal donor samples (500) </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Complete evaluation was published in 2013:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">Cooper, J.K., et al., </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Evaluation of a test for its suitability in the diagnosis of variant Creutzfeldt-Jakob disease.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Vox Sang, 2013. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">105</span><span style="font-family:'Times New Roman'; font-size:11pt">(3): p. 196-204.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Company B</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="display:none; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Spiked panel sets (</span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> tissue homogenates in pooled human plasma, </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2009</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">48 samples)</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Sheep plasma samples (</span><span style="font-family:'Times New Roman'; font-size:11pt">Scrapie</span><span style="font-family:'Times New Roman'; font-size:11pt">, BSE infected and Control; total 250)</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2009</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">UK donor plasma (2000 samples, unfrozen (1000); frozen (1000)</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2011</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Variant CJD plasma (2 samples)</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">plus 200 normal US donor plasma </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2012</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">samples</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Other tests evaluated (research and commercial) </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">9 groups provided with detergent-extracted plasma (48 samples)</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2004</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">12 groups provided with spiked plasma panel (</span><span style="font-family:'Times New Roman'; font-size:11pt">cryo</span><span style="font-family:'Times New Roman'; font-size:11pt">-depleted</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2006/2007</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt"> pooled plasma, 48 samples)</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">6 groups provided with spiked panel set using pooled whole plasma</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2007/8/9/10</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Following evaluation of the blinded sample sets, problems with sensitivity, specificity and reproducibility were identified.  Results for these studies were published in 2012 in:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">Cooper, J.K., K. Ladhani, and P. Minor, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Comparison of candidate vCJD in vitro diagnostic assays using identical sample sets.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Vox Sang, 2012. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">102</span><span style="font-family:'Times New Roman'; font-size:11pt">(2): p. 100-9.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Research groups (X5) all still currently active</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Spiked panel sets (</span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> tissue homogenates in pooled human plasma, total samples 24) </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2011/12</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Sheep </span><span style="font-family:'Times New Roman'; font-size:11pt">buffy</span><span style="font-family:'Times New Roman'; font-size:11pt"> coat preparations (</span><span style="font-family:'Times New Roman'; font-size:11pt">scrapie</span><span style="font-family:'Times New Roman'; font-size:11pt"> and control, 12 samples sent) to</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2013</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Commercial developers (X1</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Spiked panel sets (</span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> tissue homogenates in human pooled plasma, total samples 24)</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">2013</span></p><p style="margin:0pt 0pt 0pt 32.2pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div></body></html>